Amy. Thank you so much
our analysts begin our for for great we’re us first a our covering been as shareholders update. joining thank research well of It new story. First I results to call want and group Evofem very institutional thrilled welcome as a who has quarterly everyone and financial our exciting recently year to
health BV. tell better and be the will you And going SPI our you going information of I’m with to I’m the world to team in short you on we’re finally is in be being all about study the our of idea an you I contraceptive for you going additional to Amphora on conducting. update asset update I’m am our a our I’m to I'm be to going of for lot end satisfaction share our place. who to to a women, going briefly of today study and a consists going talk who amount that you Evofem. expects will about closer to describe So survey to share vaginal time. on going I’m
started. get let’s So
our Evofem reproductive mission the health. develop with unmet sexual commercialize women to core and that products need and is of address So
lead candidate considered adhesive a introduction normal vaginal even X.X healthy controlled range X.X, hormone and It’s semen. a a gel, of demand is bio free and pH women which on is women’s Amphora. vaginal is what product with and to Our it the maintains
Amphora So bit tampon this it’s cervix in Amphora it’s it’s inhospitable viral must the subsequent gel range infections to maintaining it’s also very with applicators, inserted to are bacterial any pH the of a it adheres women’s to after it vagina and environment very translucent a creates be and using is prefilled an used inhospitable viscous method. many reapplied and women like sperm a because that’s the applicator the surface many-many like Chlamydia. into and transmitted a sex, associated it’s after Amphora discreet sex and pathogens little comes provides and sexually while vaginal is the both of and an vagina to ejaculation. for having hour before an on-demand within lubrication a
the was women to initiated strides significant in we’ve that we for confirmatory in the clinical patient reached still the Amphora effective campaign fully a enrollment this so when XXX made for year; past and trial enrolled enter we X our had our trial team’s clinical target recruitment Phase of Amphora we’ve past development wanting contraception; February. So extra
a FDA study of we’re of quarter as of expect Act NDA aged months, schedule year. next have line the results positive so top forward in X,XXX advancing expect is the refile and -- at in FDA’s those the six review our enrolled the States; year; we looking results we User a a fourth to the the XXXX; this total study is reporting we sites in to contraception United in half Amphora to contraceptive sorry to first decision with of for women XXX this XX the Fee under at of ahead So so times XX Drug as the Prescription end
only contraceptive first prescription us enable in first be launch the non-hormonal and will controlled U.S. will the in and the on-demand XXXX quarter approval Amphora again early So to of women it the drug.
you innovation, but team I tell the it’s of beginning innovation. to about with you to very-very because about team going also amazing said an this about important just in little think not I are So, that execute who the people it’s having I bit it’s to was are going the
and the research; Medical prevention Affairs, our Howard for and an TEVA. held a we’ve Barrans Medical as over because positions trials our roles successful Director Plan that Planned President Organon she industry; what relevant team assembled contraceptive Commercial pharmaceutical health at Advisor Health and Officer, women’s held a of a level are STI and he who overseeing of Parenthood Russ positions leadership the the launching at Vice and and our science well she the clinical Officer, was served Federation and too TEVA, Head Bayer, expertise Global as XX it’s Brandi senior she medical Medical Medical was Chief globally; contraceptive she Officer and has Chief over women’s is oversees Senior Kelly an have and really trials International XX Mirena companies, specialization Health Organization; our and has Affairs in World of Dr. for unparalled [YS], she included grounded B; overseen responsible incredible thinking; health; as liaisons for of in So is TEVA, innovations like U.S. large really Medical has XXX keeps U.S. OBGYN Development years to important years and in global domestic has the it Medical us really Culwell she’s Clinical in Women’s Duramed, her contraceptive providers
people to call for the are yes every a women’s person, want understands course that we whole three have to how do the health; organization a take and that I wouldn’t successfully our passion Amphora. at you this single hear people, team in theme but So, I every of could. this I is We’ve talented relevant we’ve to commercialize deep overarching and just experience, it asset of level but team these really very
So this is and Amphora attractive our makes the it non-hormonal market who women an of is option. research indicates aspect that what Amphora controlled women,
now I want the billion pregnant are themselves them against U.S.; pregnant protect the in road women the of so on contraception who at using okay, meets frame rubber hormonal where it million the year. But to make XX.X have category. here for relative one up within are I of nothing women of The XX are And risk this, becoming places getting call There are is you, risk meanwhile XX those million so million contraception, to nothing majority really So think. this who at pregnancy. them women hormonal contraception. this $X.X the are right at XX% the stopped currently doing there’re doing who using those and women tried
exposure increased possible They us. they and perceived Also these to prolonged about rhythm risk women X.X have that hormonal clearly additional So risk withdraw nonprescription effects. like million compared the concerned to is what are using side and women methods of of here an hormone method, are contraception have the condom. the who less said, pregnancy there is said
So this could benefit Amphora. represented XX total women of from who potentially million
what fall the believe categories. of think, we is into here two we adaptors So will early Amphora
side weight The their effects have want their they will women of wanting. doing their don’t switch really who loss and the are impact of real, hormonal are It undesirable of contraception the side to effects contraception. throughout in and will And breast and women are their Women nothing due be their they four contraception. acne, first women currently lasting These meat hormones gain, three hormone headaches, an who their is are Hormones in exposure side of because options prolonged effects. These future don’t fertility. sexual hormones. it women left going milk, cause they're concerned tenderness times to to they lot reported seeking experience to a bloating, it to women don’t have alternative you about in tell desire. on lifetime
to So Amphora to greatly appeal these women. going is
birth as are contraception. that group be we believe of current of use of control an their Amphora properties to of protection would second XX% indicated current women method an the added lubricating So to will with we form women. their Amphora. surveyed Amphora women the These addition of together important who
so breaks forget do And condoms their withdraw. honest, to pills women take fail and partners to be and let's
a added viscous Amphora lubrication gel. with highly bio back reliable the is So adhesive up its benefit provided with of
They only we are demand approved to look prescription the use offering they it contraceptive need controlled we will product. forward hormonal first non when on women it. women if So
I about beginning. to a So in mentioned bit talk the little I survey want to the you
because Satisfaction actually Experience So our in confidence we our this commissioned findings bolstered early Survey. User is
So conducted the I women long is survey know with what study. being it is. The here who but title a that’s basically have is completed
us Empower that is the if the Now talk study. about Empower hear we call study you so contraceptive
XX% the research their completed women already trial talked initial talked at of Amphora we we friend. that are women XX% study have the and would The the a Amphora said their through who completed satisfied than or indicates who more satisfied to and looked we investigators. with highly women So partners and partners recommend to than male more of responses study they to male
sharing have an once study we to looking of So the opportunity to the are this completers concludes survey. the forward Empower these to findings and fruitality respond
based desire a non seen very we everything amongst date of potential to who So Amphora we hormonal about are method. on and identified have women optimistic the need
to going now shift FTI. bit I’m a So toward little
potential asset. alongside So developing -- working to the and this are this and trial lifecycle of label managing expanding contraceptive our also Amphora the by we maximize
to transmitted on prevent So sexually in prior of we we build Amphora are are positive a trial evaluating going studies findings and Xb Phase two infections. common our clinical to
Amphora So XX placebo. the it’s of women centers. granted with In statistically fast the XX trial Chlamydia XX Primary designation Amphora FDA for show for placebo us treated XXX to February a with a of Chlamydia. is ages arm at significant in to endpoints for rate prevention infection the blinded women double track versus in difference controlled
that this CDC more So cases infections million actually X.X preventative need alone Chlamydia XXXX, estimates there year. the us that new says million significant are and a there to for And like therapy is were in the they X.X of Amphora. every a believes in FDA what than U.S. is the
of the second Chlamydia development viability going label also asset. contraception vaginal commercial in and our sexually of prevention to for in the a the transmitted we is advancing diagnosis be It’s of for recurrent we're the excited to of BD. to potential And maximize product really finally, prevention multipurpose intended candidate. believe appeal Amphora these the of for look forward prevention to the lead technology going then indications pipeline expansion commonly and pregnancy the and really Amphora's include the of of referred prevention as to we first So the gel And future. to includes bacterial really infection successful and both in prevention additional
administration. do reduced PH a it for our a study product X seven candidate single up So days was Phase BD finding dose to and and following did study we vaginal a
most This it is also though So category we as to on our continue will this going to the the explore more a as to resources Amphora focus product can strategically first. be of importantly that NDA approval want in an in, opportunities get capital but that separate we is invest additional asset a underserved. contraceptive we very we're
So in closing, value to that for where our investments are shareholders for serve. focusing for we most and and can build the we our on we company we believe patients rapidly aim
turn the that going I'm over So to Jay with CFO call File. our to
